Management of progressive metastatic prostate cancer.
Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men. While the response of patients with metastatic prostate cancer to initial hormonal manipulation is excellent, the majority of patients eventually progress. As a result, a growing number of patients and their physicians need-to-find acceptable therapeutic alternatives. Fortunately, the number of therapies in the management armamentarium is growing and includes: alternative hormonal therapies, chemotherapy, radioisotopes, and investigational agents. The major focus of treatment has shifted to palliation and quality of life. The decline of prostate-specific antigen (PSA) has become another important end point as evidence supporting a correlation with prolonged survival mounts. Enrolling eligible patients in clinical trials is critical to the development of new treatment strategies for this difficult disease.
Waselenko
J K
JK
Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, DC, USA.
Dawson
N A
NA
D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use; D018450:Disease Progression; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D011788:Quality of Life; D013375:Substance Withdrawal Syndrome; D013498:Suramin / Q000627:therapeutic use; D013737:Testis / Q000378:metabolism
D000726:Androgen Antagonists; D000728:Androgens; D004164:Diphosphonates; D006728:Hormones; D013498:Suramin